Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
500
Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo
Neukidney Inc
Rosharon, Texas, United States
Rate of change in creatinine glomerular filtration rate
compare the outcome effect of added QRX-3 drug to placebo in addition to standard therapy on the rate of change from baseline of creatinine GFR in ATN patients
Time frame: 28 days
daily change in glomerular filtration rate in ml/min
daily change in GFR by creatinine in mls/min
Time frame: 7 days
daily change in cystatin C level in mg/dl
daily change in measured cystatin C level
Time frame: 7 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.